Latest Milestone Payments News

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Lithium Universe (ASX: LU7) has acquired exclusive global rights to a University of Edinburgh hydrometallurgical process that extracts gold and copper from electronic waste using recyclable organic compounds, positioning the company at the forefront of sustainable precious metals recovery.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Forrestania Resources has secured a strategic gold tenure package in Western Australia's Newington district through a $1.5 million share-based acquisition of Midas Minerals’ Newington project, complemented by milestone-linked deferred payments.

Avecho Biotechnology has wrapped up the treatment phase for its pivotal Phase III insomnia trial involving 244 participants, setting the stage for an interim efficacy analysis expected in late June 2026.

OD6 Metals is progressing its acquisition option for the Quinn Fluorspar Project in Nevada, a high-grade fluorspar asset poised to address the United States' complete import reliance on this critical mineral vital to semiconductor, battery, and defense sectors.

Locksley Resources has secured an option to acquire 100% of the Iron Duke Copper & Gold Project near its Tottenham asset, adding an inferred resource of 1.3 million tonnes grading 1.0% copper and 0.6 g/t gold. The low-cost, milestone-based deal supports a district-scale exploration strategy in the Cobar region.

Micro-X's U.S. subsidiary has won a $1.3 million contract extension from the U.S. Department of Homeland Security to push forward its Passenger Self-Screening Checkpoint program, moving closer to real-world airport trials.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Locksley Resources has secured an option to acquire the Iron Duke Copper & Gold Project in NSW, enhancing its district-scale strategy near Tottenham with high-grade mineralisation and multiple drill-ready targets.

Alicanto Minerals has struck strategic earn-in agreements for its Swedish projects potentially worth A$21 million, while expanding its Mt Henry Gold Project footprint in Western Australia and proposing a name change to Sinclair Gold.